A5078997459- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- COVID-19 Clinical Research Studies
- T-cell and B-cell Immunology
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Neutropenia and Cancer Infections
- Cytomegalovirus and herpesvirus research
- Herpesvirus Infections and Treatments
- Gastrointestinal Tumor Research and Treatment
- Immunodeficiency and Autoimmune Disorders
- Chronic Myeloid Leukemia Treatments
- Advanced Breast Cancer Therapies
- SARS-CoV-2 and COVID-19 Research
- COVID-19 and healthcare impacts
- Immune Cell Function and Interaction
Turku University Hospital
2018-2024
Varsinais-Suomen Sairaanhoitopiiri
2022
University of Turku
2020
Abstract Purpose In clinical practice, we observed an apparent overrepresentation of COVID-19 patients on anti-CD20 monoclonal antibody therapy. The aim this study was to characterize the picture in these patients. Methods All adult from Turku University Hospital, Turku, Finland, with diagnosis and/or positive SARS-CoV-2 PCR test result up March 2023, and therapy within 12 months before were included. Data retrospectively obtained electronic patient records. Results Ninety-eight identified....
In this single-center study we retrospectively evaluated the impact of early reconstitution different lymphocyte subsets on patient outcomes after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We found that CD8+ T-cell counts exceeding 50x10(6)/l as day 28 post-transplantation correlated significantly with decreased relapse risk, three-year rates 17.0% and 55.6% (P = 0.002), but were also associated severe acute chronic GVHD. Incidence grade III-IV GVHD was 30.5% for those...
Introduction Literature is scarce on the combination treatment of ibrutinib and venetoclax (IV) in relapsed or refractory chronic lymphocytic leukaemia (RR-CLL). Especially, possibility stopping RR-CLL patients deep remission unclear. Methods analysis In HOVON 141/VISION trial, with are treated 12 cycles IV after a short induction ibrutinib. Patients reaching undetectable minimal residual disease (uMRD) randomised 1:2 to continue stop treatment. The persistence uMRD studied. addition, who...
Background: In patients with relapsed/refractory (RR) CLL efficacy and safety of MRD guided treatment cessation venetoclax+ibrutinib (V+I) the option to reinitiate V+I based on reappearance was evaluated in randomized Phase 2 Ho141/VISION study. Primary analysis, when last patient reached 27 months, showed a favorable benefit-risk profile reinduction (Lancet Oncol 2022). Aims: To analyze long-term clinical outcome MRD-kinetics median follow up 50.8 months for enrolled VISION trial. Methods:...
CMV infection is a common complication in allogeneic hematopoietic stem cell transplantation (HSCT). We investigated the association of clinically significant (CS-CMV) with clinical outcomes and healthcare resource utilization HSCT patients Finland.This retrospective study included adult who received their first between January 1, 2013, December 31, 2018, at Turku University Hospital. Data were collected from hospital data lake. Clinical one year mortality up to three years.The 251 patients....
Abstract Our retrospective study (2010–2020) examined treatment patterns, outcomes, and healthcare resource utilization in Finnish acute myeloid leukemia (AML) patients. Data covered 153 patients diagnosed at Hospital District of Southwest Finland (HDSF) 107 from other districts who underwent allogeneic stem cell transplantation (aSCT) HDSF. Of the patients, 56.2% received intensive chemotherapy (IC), while 43.8% deemed ineligible for IC low‐intensity therapies or best supportive care (BSC)....
Background: Although targeted therapies have made a breakthrough in CLL treatment, many patients develop resistance, severe side effects, or relapse during treatment. Due to the wide heterogeneity both clinicobiological features and clinical outcomes, require personalized management strategies. HOVON 141/VISION is randomized phase II trial that evaluates efficacy of minimal residual disease (MRD) guided combinatorial treatment with Bcl-2 antagonist venetoclax BTK inhibitor ibrutinib...